Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases

Gastroenterology

Volumn 140, Issue 6, 2011, Pages 1776-1784.e5

  Villablanca, Eduardo J ^a   Cassani, Barbara ^a   Von Andrian, Ulrich H ^b   Mora, J Rodrigo ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CCR9; Crohn's Disease; IBD; Ulcerative Colitis; 4 7

Indexed keywords

AJM 300; ALICAFORSEN; ALPHA4 INTEGRIN ANTIBODY; ALPHA4BETA7 INTEGRIN; ANTIINFLAMMATORY AGENT; CCL25 CHEMOKINE; CCX 282 B; CHEMOKINE; CHEMOKINE RECEPTOR CCR9; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 00547659; PF 0547659; TRAFICET EN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1 ANTIBODY; VEDOLIZUMAB;

ARTICLE; B LYMPHOCYTE; CROHN DISEASE; DRUG MECHANISM; ENTERITIS; GASTROINTESTINAL MUCOSA; HUMAN; LYMPHOCYTE HOMING; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 79955562264     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.02.015     Document Type: Article

References (124)

1. U.H. von Andrian, and C.R. Mackay T-cell function and migration Two sides of the same coin N Engl J Med 343 2000 1020 1034
2. J.R. Mora, and U.H. von Andrian Differentiation and homing of IgA-secreting cells Mucosal Immunol 1 2008 96 109
3. J.R. Mora, M. Iwata, and U.H. von Andrian Vitamin effects on the immune system: vitamins A and D take centre stage Nat Rev Immunol 8 2008 685 698
4. J.R. Mora Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids Inflamm Bowel Dis 14 2008 275 289 (Pubitemid 351288051)
5. D. Masopust, V. Vezys, and A.L. Marzo Preferential localization of effector memory cells in nonlymphoid tissue Science 291 2001 2413 2417 (Pubitemid 32231804)
6. J.R. Mora, and U.H. von Andrian T-cell homing specificity and plasticity: new concepts and future challenges Trends Immunol 27 2006 235 243 (Pubitemid 44308124)
7. H. Stenstad, M. Svensson, and H. Cucak Differential homing mechanisms regulate regionalized effector CD8alphabeta+ T cell accumulation within the small intestine Proc Natl Acad Sci U S A 104 2007 10122 10127 (Pubitemid 47175273)
8. N. Wright, A. Hidalgo, and J.M. Rodriguez-Frade The chemokine stromal cell-derived factor-1 alpha modulates alpha 4 beta 7 integrin-mediated lymphocyte adhesion to mucosal addressin cell adhesion molecule-1 and fibronectin J Immunol 168 2002 5268 5277 (Pubitemid 34495995)
9. F. Annunziato, L. Cosmi, and F. Liotta CXCR3 and alphaEbeta7 integrin identify a subset of CD8+ mature thymocytes that share phenotypic and functional properties with CD8+ gut intraepithelial lymphocytes Gut 55 2006 961 968 (Pubitemid 43962607)
10. T. Oyama, S. Miura, and C. Watanabe CXCL12 and CCL20 play a significant role in mucosal T-lymphocyte adherence to intestinal microvessels in mice Microcirculation 14 2007 753 766 (Pubitemid 47434290)
11. J. Rodrigo Mora, and U.H. Von Andrian Specificity and plasticity of memory lymphocyte migration Curr Top Microbiol Immunol 308 2006 83 116 (Pubitemid 47400298)
12. E.J. Kunkel, J.J. Campbell, and G. Haraldsen Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity J Exp Med 192 2000 761 768
13. K.A. Papadakis, J. Prehn, and V. Nelson The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system J Immunol 165 2000 5069 5076
14. C. Wang, S.G. Kang, and H. HogenEsch Retinoic acid determines the precise tissue tropism of inflammatory Th17 cells in the intestine J Immunol 184 2010 5519 5526
15. H. Stenstad, A. Ericsson, and B. Johansson-Lindbom Gut associated lymphoid tissue primed CD4+ T cells display CCR9 dependent and independent homing to the small intestine Blood 107 2006 3447 3454
16. C. Wang, S.G. Kang, and J. Lee The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut Mucosal Immunol 2 2009 173 183
17. S.G. Kang, H.W. Lim, and O.M. Andrisani Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells J Immunol 179 2007 3724 3733
18. M.J. Benson, K. Pino-Lagos, and M. Rosemblatt All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation J Exp Med 2007 17751774
19. H.R. Cha, S.Y. Chang, and J.H. Chang Downregulation of Th17 cells in the small intestine by disruption of gut flora in the absence of retinoic acid J Immunol 184 2010 6799 6806
20. S.G. Kang, C. Wang, and S. Matsumoto High and low vitamin A therapies induce distinct FoxP3+ T-cell subsets and effectively control intestinal inflammation Gastroenterology 137 2009 1391 1402 e1-6
21. E.J. Kunkel, and E.C. Butcher Plasma-cell homing Nat Rev Immunol 3 2003 822 829 (Pubitemid 37328660)
22. O. Pabst, L. Ohl, and M. Wendland Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine J Exp Med 199 2004 411 416 (Pubitemid 38252052)
23. K. Hieshima, Y. Kawasaki, and H. Hanamoto CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells J Immunol 173 2004 3668 3675 (Pubitemid 39280727)
24. J.R. Mora, M. Iwata, and B. Eksteen Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells Science 314 2006 1157 1160 (Pubitemid 44789048)
25. S. Uematsu, K. Fujimoto, and M.H. Jang Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5 Nat Immunol 9 2008 769 776 (Pubitemid 351859160)
26. T. Shigematsu, R.D. Specian, and R.E. Wolf MAdCAM mediates lymphocyte-endothelial cell adhesion in a murine model of chronic colitis Am J Physiol Gastrointest Liver Physiol 281 2001 G1309 G1315
27. S. Kawachi, Z. Morise, and S.R. Jennings Cytokine and adhesion molecule expression in SCID mice reconstituted with CD4+ T cells Inflamm Bowel Dis 6 2000 171 180
28. K. Matsuzaki, Y. Tsuzuki, and H. Matsunaga In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1 Clin Exp Immunol 140 2005 22 31 (Pubitemid 40461069)
29. J. Rivera-Nieves, T. Olson, and G. Bamias L-selectin, alpha4beta1, and alpha4beta7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine J Immunol 174 2005 2343 2352
30. H.S. Souza, C.C. Elia, and J. Spencer Expression of lymphocyte- endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease Gut 45 1999 856 863
31. S. Arihiro, H. Ohtani, and M. Suzuki Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease Pathol Int 52 2002 367 374 (Pubitemid 34748219)
32. M. Apostolaki, M. Manoloukos, and M. Roulis Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease Gastroenterology 134 2008 2025 2035 (Pubitemid 351790742)
33. A. Goto, Y. Arimura, and Y. Shinomura Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis Inflamm Bowel Dis 12 2006 758 765 (Pubitemid 44253761)
34. D. Picarella, P. Hurlbut, and J. Rottman Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells J Immunol 158 1997 2099 2106 (Pubitemid 127469991)
35. P.E. Hesterberg, D. Winsor-Hines, and M.J. Briskin Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7 Gastroenterology 111 1996 1373 1380 (Pubitemid 26362264)
36. D.K. Podolsky, R. Lobb, and N. King Attenuation of colitis in the cotton top tamarin by anti-a4 integrin monoclonal antibody J Clin Invest 92 1993 372 380 (Pubitemid 23209018)
37. G. Gorfu, J. Rivera-Nieves, and S. Hoang Beta7 integrin deficiency suppresses B cell homing and attenuates chronic ileitis in SAMP1/YitFc mice J Immunol 185 2010 5561 5568
38. S. Fiorucci, A. Mencarelli, and B. Palazzetti Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis Immunity 17 2002 769 780 (Pubitemid 35477796)
39. S. Farkas, M. Hornung, and C. Sattler Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis Int J Colorectal Dis 21 2006 71 78 (Pubitemid 41829768)
40. S. Kato, R. Hokari, and K. Matsuzaki Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1 J Pharmacol Exp Ther 295 2000 183 189
41. T. Taniguchi, H. Tsukada, and H. Nakamura Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats J Gastroenterol Hepatol 13 1998 945 949 (Pubitemid 28448968)
42. A. Soriano, A. Salas, and M. Sans VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice Lab Invest 80 2000 1541 1551
43. T.S. Olson, G. Bamias, and M. Naganuma Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease J Clin Invest 114 2004 389 398 (Pubitemid 39071611)
44. T.L. Denning, G. Kim, and M. Kronenberg Cutting edge: CD4+CD25+ regulatory T cells impaired for intestinal homing can prevent colitis J Immunol 174 2005 7487 7491 (Pubitemid 40806250)
45. M.A. Schneider, J.G. Meingassner, and M. Lipp CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells J Exp Med 204 2007 735 745 (Pubitemid 46631604)
46. Q. Yuan, S.K. Bromley, and T.K. Means CCR4-dependent regulatory T cell function in inflammatory bowel disease J Exp Med 204 2007 1327 1334 (Pubitemid 46919871)
47. C. Mottet, H.H. Uhlig, and F. Powrie Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells J Immunol 170 2003 3939 3943 (Pubitemid 36428153)
48. S.G. Kang, R.J. Piniecki, and H. Hogenesch Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine Gastroenterology 132 2007 966 981 (Pubitemid 46454268)
49. K.A. Papadakis, J. Prehn, and S.T. Moreno CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease Gastroenterology 121 2001 246 254 (Pubitemid 32729371)
50. J. Rivera-Nieves, J. Ho, and G. Bamias Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis Gastroenterology 131 2006 1518 1529 (Pubitemid 44708936)
51. E.J. Kunkel, and E.C. Butcher Chemokines and the tissue-specific migration of lymphocytes Immunity 16 2002 1 4 (Pubitemid 34143211)
52. M. Sans, S. Danese, and C. de la Motte Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease Gastroenterology 132 2007 139 153 (Pubitemid 46108734)
53. 3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow J Exp Med 188 1998 1413 1419 (Pubitemid 28489578)
54. F.I. Kostadinova, T. Baba, and Y. Ishida Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice J Leukoc Biol 88 2010 133 143
55. D.H. Adams, and B. Eksteen Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease Nat Rev Immunol 6 2006 244 251 (Pubitemid 43290993)
56. A. Stallmach, S. Hagel, and T. Bruns Adverse effects of biologics used for treating IBD Best Pract Res Clin Gastroenterol 24 2010 167 182
57. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
58. P. Diak, J. Siegel, and L. La Grenade Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration Arthritis Rheum 62 2010 2517 2524
59. S. Massberg, and U.H. von Andrian Fingolimod and sphingosine-1- phosphatemodifiers of lymphocyte migration N Engl J Med 355 2006 1088 1091
60. M.P. Schon, C. Drewniok, and W.H. Boehncke Targeting selectin functions in the therapy of psoriasis Curr Drug Targets Inflamm Allergy 3 2004 163 168 (Pubitemid 38832746)
61. M. Lebwohl, S.K. Tyring, and T.K. Hamilton A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013 (Pubitemid 37448923)
62. E. Sawicka, C. Zuany-Amorim, and C. Manlius Inhibition of Th1- and th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720 J Immunol 171 2003 6206 6214 (Pubitemid 37467244)
63. E. Waldman, S.X. Lu, and V.M. Hubbard Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine Blood 107 2006 1703 1711 (Pubitemid 43242412)
64. A.F. Kavanaugh, L.S. Davis, and L.A. Nichols Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1 Arthritis Rheum 37 1994 992 999 (Pubitemid 24222089)
65. N. Hamamoto, K. Maemura, and I. Hirata Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)) Clin Exp Immunol 117 1999 462 468 (Pubitemid 29398291)
66. R.C. Burns, J. Rivera-Nieves, and C.A. Moskaluk Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice Gastroenterology 121 2001 1428 1436 (Pubitemid 33140460)
67. B.R. Yacyshyn, M.B. Bowen-Yacyshyn, and L. Jewell A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease Gastroenterology 114 1998 1133 1142 (Pubitemid 28243898)
68. S. Schreiber, S. Nikolaus, and H. Malchow Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease Gastroenterology 120 2001 1339 1346 (Pubitemid 32322307)
69. B.R. Yacyshyn, W.Y. Chey, and J. Goff Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut 51 2002 30 36 (Pubitemid 34717740)
70. S.J. van Deventer, J.A. Tami, and M.K. Wedel A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis Gut 53 2004 1646 1651 (Pubitemid 39434109)
71. U.H. von Andrian, and B. Engelhardt Alpha4 integrins as therapeutic targets in autoimmune disease N Engl J Med 348 2003 68 72 (Pubitemid 36026351)
72. S. Ghosh, E. Goldin, and F.H. Gordon Recombinant humanized antibody to a4 integrin (Natalizumab) in the treatment of active Crohn's disease N Engl J Med 348 2003 24 321
73. W.J. Sandborn, J.F. Colombel, and R. Enns Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 2005 1912 1925 (Pubitemid 41565956)
74. S.R. Targan, B.G. Feagan, and R.N. Fedorak Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterology 132 2007 1672 1683 (Pubitemid 46695722)
75. F.H. Gordon, M.I. Hamilton, and S. Donoghue A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin Aliment Pharmacol Ther 16 2002 699 705 (Pubitemid 34407517)
76. D.H. Miller, O.A. Khan, and W.A. Sheremata A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 2003 15 23 (Pubitemid 36026342)
77. T.A. Yednock, C. Cannon, and L.C. Fritz Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin Nature 356 1992 63 66
78. G. Van Assche, M. Van Ranst, and R. Sciot Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 2005 362 368 (Pubitemid 41132340)
79. T.A. Yousry, E.O. Major, and C. Ryschkewitsch Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 2006 924 933
80. A. Laroni, M. Bedognetti, and A. Uccelli Association of melanoma and natalizumab therapy in the Italian MS population: a second case report Neurol Sci 32 2011 181 182
81. A. Ismail, J. Kemp, and B. Sharrack Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis J Neurol 256 2009 1771 1772
82. M. Takazoe, M. Watanabe, and T. Kawaguchi Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's diseasea randomized, double-blind, placebo-controlled trial Gastroenterology 136 2009 A181 (Abstract S1066)
83. E.O. Major Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies Annu Rev Med 61 2010 35 47
84. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin N Engl J Med 352 2005 2499 2507 (Pubitemid 41007865)
85. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin Clin Gastroenterol Hepatol 6 2008 1370 1377
86. S. Vermeire, S. Ghosh, and J. Panes Safety and efficacy of PF-00547,659, a fully human anti-MAdCAM antibody, in ulcerative colitis Results of a first in human study Gastroenterology 136 2009 A181 (Abstract S1066)
87. M.J. Walters, Y. Wang, and N. Lai Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease J Pharmacol Exp Ther 335 2010 61 69
88. B. Eksteen, and D.H. Adams GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease IDrugs 13 2010 472 781
89. H. Hadeiba, T. Sato, and A. Habtezion CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease Nat Immunol 9 2008 1253 1260
90. M. Wendland, N. Czeloth, and N. Mach CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine Proc Natl Acad Sci U S A 104 2007 6347 6352 (Pubitemid 47186097)
91. P.D. Higgins, D.T. Rubin, and K. Kaulback Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares Aliment Pharmacol Ther 29 2009 247 257
92. S.V. Kane, R.D. Cohen, and J.E. Aikens Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis Am J Gastroenterol 96 2001 2929 2933 (Pubitemid 32959535)
93. P.M. Irving, R.B. Gearry, and M.P. Sparrow Review article: appropriate use of corticosteroids in Crohn's disease Aliment Pharmacol Ther 26 2007 313 329 (Pubitemid 47063143)
94. J.B. Chevaux, L. Peyrin-Biroulet, and M.P. Sparrow Optimizing thiopurine therapy in inflammatory bowel disease Inflamm Bowel Dis 2010 Oct 14 [Epub ahead of print]
95. E.A. Maser, D. Deconda, and S. Lichtiger Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis Clin Gastroenterol Hepatol 6 2008 1112 1116
96. W. Cacheux, P. Seksik, and M. Lemann Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis Am J Gastroenterol 103 2008 637 642 (Pubitemid 351405993)
97. M. Wahed, J.R. Louis-Auguste, and L.M. Baxter Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine Aliment Pharmacol Ther 30 2009 614 620
98. D.M. Nathan, J.H. Iser, and P.R. Gibson A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration J Gastroenterol Hepatol 23 2008 954 958 (Pubitemid 351806563)
99. B.E. Sands, F.H. Anderson, and C.N. Bernstein Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876 885 (Pubitemid 38252535)
100. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476 (Pubitemid 41770166)
101. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
102. P. Diak, J. Siegel, and L. La Grenade Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration Arthritis Rheum 62 2010 2517 2524
103. W.J. Sandborn, S.B. Hanauer, and P. Rutgeerts Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239 (Pubitemid 47300424)
104. S. Travis, L.M. Yap, and C. Hawkey RDP58 is a novel and potentially effective oral therapy for ulcerative colitis Inflamm Bowel Dis 11 2005 713 719 (Pubitemid 41271174)
105. S. Schreiber, M. Khaliq-Kareemi, and I.C. Lawrance Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 2007 239 250 (Pubitemid 47080388)
106. W.J. Sandborn, B.G. Feagan, and S. Stoinov Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 2007 228 238 (Pubitemid 47080387)
107. F.J. Dumont IDEC-131 IDEC/Eisai Curr Opin Investig Drugs 3 2002 725 734 (Pubitemid 36266823)
108. J. Emmrich, M. Seyfarth, and W.E. Fleig Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody Lancet 338 1991 570 571
109. V. Canva-Delcambre, S. Jacquot, and E. Robinet Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody Aliment Pharmacol Ther 10 1996 721 727 (Pubitemid 26340201)
110. A. Stronkhorst, S. Radema, and S.L. Yong CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study Gut 40 1997 320 327 (Pubitemid 27145643)
111. S. Plevy, B. Salzberg, and G. Van Assche A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis Gastroenterology 133 2007 1414 1422 (Pubitemid 350029746)
112. D.C. Baumgart, S.R. Targan, and A.U. Dignass Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis Inflamm Bowel Dis 16 2010 620 629
113. H. Braat, M.P. Peppelenbosch, and D.W. Hommes Interleukin-10-based therapy for inflammatory bowel disease Expert Opin Biol Ther 3 2003 725 731 (Pubitemid 36934972)
114. B.E. Sands, B.D. Winston, and B. Salzberg Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease Aliment Pharmacol Ther 16 2002 399 406 (Pubitemid 34214518)
115. K.R. Herrlinger, T. Witthoeft, and A. Raedler Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease Am J Gastroenterol 101 2006 793 797
116. C. Ding, and G. Jones Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases Rev Recent Clin Trials 1 2006 193 200
117. D.W. Hommes, T.L. Mikhajlova, and S. Stoinov Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease Gut 55 2006 1131 1137 (Pubitemid 44085681)
118. W. Reinisch, D.W. Hommes, and G. Van Assche A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease Gut 55 2006 1138 1144 (Pubitemid 44085682)
119. P.J. Mannon, I.J. Fuss, and L. Mayer Anti-interleukin-12 antibody for active Crohn's disease N Engl J Med 351 2004 2069 2079 (Pubitemid 39482500)
120. A.E. Slonim, L. Bulone, and M.B. Damore A preliminary study of growth hormone therapy for Crohn's disease N Engl J Med 342 2000 1633 1637 (Pubitemid 30341532)
121. A. Sinha, J. Nightingale, and K.P. West Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis N Engl J Med 349 2003 350 357 (Pubitemid 36886241)
122. B.K. Dieckgraefe, and J.R. Korzenik Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor Lancet 360 2002 1478 1480 (Pubitemid 35356328)
123. J.R. Korzenik, B.K. Dieckgraefe, and J.F. Valentine Sargramostim for active Crohn's disease N Engl J Med 352 2005 2193 2201 (Pubitemid 40727086)
124. J.R. Korzenik, and B.K. Dieckgraefe An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease Aliment Pharmacol Ther 21 2005 391 400 (Pubitemid 40313941)